Day Competitors
| DAWN Stock | USD 21.31 0.04 0.19% |
Pair Correlation for Day One and Vir Biotechnology Details
Poor diversification
Across the chosen horizon, DAWN and VIR show a correlation of 0.71 and fall into the Poor diversification bucket. The overlap area represents the portion of risk that may be diversified away when both instruments are held together and nothing else in the portfolio changes.
Moving against Day Stock
The mean reversion tendency in Day One's price is a well-documented phenomenon that disciplined investors can exploit by identifying when price has diverged substantially from fundamental and historical anchors.
Day One Competition Correlation Matrix
Correlation analysis between Day One Biopharmaceuticals and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Day Stock performing well and Day One Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Day One's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GERN | 3.37 | 0.51 | 0.11 | 0.22 | 3.68 | 8.59 | 24.20 | |||
| VALN | 2.90 | 0.36 | 0.11 | 0.31 | 3.03 | 6.85 | 16.68 | |||
| ARVN | 2.40 | -0.01 | 0.02 | 0.00 | 2.83 | 5.25 | 15.46 | |||
| REPL | 3.21 | -0.42 | 0.00 | 6.58 | 0.00 | 8.82 | 20.74 | |||
| TYRA | 2.55 | 0.76 | 0.32 | 6.67 | 2.03 | 6.56 | 18.83 | |||
| RZLT | 7.63 | -0.07 | 0.01 | -0.02 | 15.35 | 18.05 | 98.27 | |||
| AVBP | 2.65 | 0.01 | 0.00 | -0.03 | 0.00 | 6.71 | 18.15 | |||
| ATXS | 1,369 | 684.14 | 622.56 | -2.82 | 0.00 | 2.15 | 6.54 | |||
| ERAS | 4.57 | 2.33 | 0.67 | -2.72 | 2.60 | 15.04 | 50.26 | |||
| VIR | 3.59 | 0.72 | 0.19 | 0.36 | 3.29 | 7.30 | 34.53 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Day One financial statement analysis. It represents the amount of money remaining after all of Day One Biopharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Select Fundamental
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GERN | -10.7 M | -96.9 M | -68.9 M | -38.4 M | -35.7 M | 46 K | -29.5 M | -27.9 M | -27 M | -63.6 M | -75.6 M | -116.1 M | -141.9 M | -184.1 M | -174.6 M | -85.8 M | -90.1 M |
| VALN | -1.2 M | -4.4 M | -14.8 M | -24.1 M | -26.3 M | -20.6 M | -49.2 M | -11.5 M | 3.3 M | -1.7 M | -64.4 M | -73.4 M | -143.3 M | -101.4 M | -12.2 M | -11 M | -11.6 M |
| ARVN | -14.4 M | -14.4 M | -14.4 M | -14.4 M | -14.4 M | -14.4 M | -14.4 M | -24 M | -41.5 M | -62.1 M | -111.8 M | -183.2 M | -271.9 M | -367.3 M | -198.9 M | -80.8 M | -84.8 M |
| REPL | -7.7 M | -7.7 M | -7.7 M | -7.7 M | -7.7 M | -7.7 M | -7.7 M | -19.7 M | -30.8 M | -52.6 M | -80.9 M | -118 M | -174.3 M | -215.8 M | -247.3 M | -222.6 M | -211.4 M |
| TYRA | -4.1 M | -4.1 M | -4.1 M | -4.1 M | -4.1 M | -4.1 M | -4.1 M | -4.1 M | -4.1 M | -4.1 M | -9.3 M | -26.1 M | -51.7 M | -69.1 M | -86.5 M | -119.9 M | -113.9 M |
| RZLT | -49.3 K | -49.3 K | -6.7 M | -9.7 M | -11.4 M | -14.9 M | -20.3 M | -29.9 M | -30.4 M | -20.3 M | -20.9 M | -41.1 M | -51.8 M | -68.5 M | -74.4 M | -67 M | -63.6 M |
| AVBP | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -36.9 M | -69.3 M | -80.5 M | -166.3 M | -149.7 M | -142.2 M |
| ATXS | -15.7 K | -15.7 K | -15.7 K | -18.1 M | -21.9 M | -32.6 M | -36.1 M | -27.4 M | -25.9 M | -26.3 M | -37.1 M | -194.9 M | -50.2 M | -72.9 M | -94.3 M | -84.8 M | -80.6 M |
| ERAS | -12 M | -12 M | -12 M | -12 M | -12 M | -12 M | -12 M | -12 M | -12 M | -12 M | -101.7 M | -122.8 M | -242.8 M | -125 M | -161.7 M | -145.5 M | -152.8 M |
| VIR | -69.9 M | -69.9 M | -69.9 M | -69.9 M | -69.9 M | -69.9 M | -69.9 M | -69.9 M | -115.9 M | -174.7 M | -298.7 M | 528.6 M | 515.8 M | -615.1 M | -522 M | -438 M | -416.1 M |
Day One Competitive Analysis
Day One competes directly with Geron, Valneva SE, and Arvinas, and the financial data points to clear areas of divergence. On scale alone, Day One's 2.20 B valuation and 158.2 M revenue define its weight class. With a -22.74% return on equity and -67.85% net margin, Day One faces a more difficult earnings environment than some peers. Market capitalization diverges sharply here: 2.20 B versus 1.01 B, giving Day One a clear size advantage. Return on equity favors Day One at -22.74%, well ahead of Valneva SE at -55.53%. Profit margins tilt toward Arvinas at -30.77% against Day One at -67.85%.| Better Than Average | Worse Than Peers | View Performance Chart |
Peer Performance Charts
How to Analyze Day One Against Peers
Day One's peer analysis compares Day One with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Day One trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Day One leads or lags and what catalysts could close or widen the gap.